HiSiaddi is an innovative foreign trade service provider driven by dual pillars of technology commercialization and cross-border trading. We have established a "1+2+3+4=1" service system and can supply succinic acid sourced directly from well-known original manufacturers. As a foreign trader with in-house R&D capabilities, HiSiaddi has conducted repeated multi-round factory inspections of succinic acid manufacturers through technology cooperation with factories, possessing objective and in-depth understanding of different brands. We regularly analyze succinic acid manufacturers for clients to help them select matching products. Below is our brand selection practical case.
Contact HiSiaddi customer service for more brand and model comparison analysis.
The buyer is NutriMed AG based in Zurich, Switzerland, a leading Western European enterprise specializing in mid-to-high-end dietary supplements and medical sustained-release nutrient solutions. With over 20 years of experience in Europe’s premium health industry, its products supply local Swiss pharmacy chains and high-end private medical institutions in Germany and Austria. All product lines comply with EP Pharmacopoeia, USP standards, EU REACH, EFSA food access regulations, FDA GRAS and ISO22000 food safety systems, representing a typical refined high-volume premium buyer with no demand for low-end bulk materials. The enterprise long sourced bio-based succinic acid directly from BASF Germany, yet initiated a China supply chain localization replacement project in 2025 amid shrinking local European chemical production capacity, surging energy and raw material costs, and extended lead times exceeding 90 days. Annual projected bio-based succinic acid procurement volume stands at 180 tons, delivered in quarterly batches across three production scenarios: sustained-release tablet excipients, oral liquid buffering agents and high-end powdered nutritional raw materials. Rigid strict thresholds apply to raw material purity, crystal form, impurity control, bio-based traceability and compliance certifications.
The client independently contacted five leading domestic succinic acid manufacturers: Cathay Biotech, BBCA Group, Shandong Landian Biological, Zhejiang Hisun Biological and Jiangxi Boneng Biological. After online and on-site factory audits and sample collection, the client encountered widespread industry selection barriers. While domestic manufacturers maintain ethical standards and avoid maliciously slandering competitors, they are constrained by production capacity structures, product line positioning and sales KPIs. All prioritize promoting their own product lines, elaborating only on their own product strengths, parameters and certifications while intentionally avoiding core advantages, applicable scenarios and drawbacks of competing brands. This fragmented information left the Swiss client confused and unable to conduct objective horizontal comparisons across all product categories.
The Swiss Procurement Director holds 22 years of industry experience and is familiar with European and American raw material quality control systems, yet lacks systematic knowledge of domestic succinic acid brand segmentation, process routes, model grading and grade differences. Domestic manufacturers fall into two major process categories: bio-fermentation and petrochemical synthesis. Each brand further subdivides into four mainstream grades: injection pharmaceutical grade, oral pharmaceutical grade, high-purity food grade and general industrial grade. Significant gaps exist between brands of identical grades in impurity indicators, crystal structure, particle size distribution, solvent residues and cost ranges, making it impossible to judge suitability relying solely on manufacturer self-promotion. Twelve samples from five brands generated three issues during laboratory small-scale trials: precipitation in low-temperature solutions, excessive fluctuation in tablet disintegration rates and powder feeding blockages, preventing compatibility with existing mass production formulations. Procurement progress stalled for two months amid an approaching new drug approval deadline. Introduced by industry peers, the client fully entrusted HiSiaddi’s foreign trade team with neutral third-party brand sorting, horizontal parameter evaluation and targeted model selection & delivery, covering full research of domestic succinic acid brands, centralized sample coordination and sourcing implementation.
Drawing on years of deep experience in organic acid foreign trade, HiSiaddi first targeted five mainstream mid-to-high-end domestic succinic acid brands: Cathay Biotech, BBCA Group, Shandong Landian Biological, Zhejiang Hisun Biological and Jiangxi Boneng Biological. We collected production line data, CNAS third-party test reports, EU compliance certificates, full-range physical and chemical indicators, production processes and application delivery cases for each enterprise. Discarding manufacturer self-promotional rhetoric, we conducted neutral horizontal breakdowns covering seven dimensions — raw material origin, refining process, impurity control, crystal particle size, compliance certifications, price range and supply stability — aligned with the client’s three end-use scenarios (sustained-release tablets, oral liquids, nutritional powders). We sorted out the strengths, applicable scenarios and inherent weaknesses of all mainstream models under each brand, compiling a bilingual Chinese-English brand selection whitepaper to eliminate information gaps for the client.
1. Core models: KS-PH oral pharmaceutical grade, KS-FO high-purity food grade, KS-IN injection high-purity grade. All adopt glucose anaerobic bio-fermentation, with no petrochemical synthesis product lines. The first domestic manufacturer to obtain dual FDA GRAS and EU EFSA access certifications, with outstanding mass production advantages and annual capacity exceeding 40,000 tons. Extremely stable batch consistency with minimal physical-chemical fluctuation per batch; complete raw material traceability system capable of issuing bio-based carbon content test reports batch by batch.
2. Product strengths: KS-FO food grade features uniform regular crystals with low dust generation, resisting caking during automated feeding and suitable for large-batch powder production lines. KS-PH pharmaceutical grade limits fumaric acid and maleic acid by-products ≤0.02%, far below national standard limits.
3. Inherent drawbacks: Ultra-high-purity KS-IN injection grade carries a premium price and lacks flexible small-batch production capabilities with a minimum order quantity of 30 tons, unsuitable for small-batch new formulation testing.
1. Core models: FY-MED pharmaceutical grade, FY-FO refined food grade. Leverage self-owned corn and straw raw material bases with full in-house production from starch saccharification to fermentation, delivering industry-leading raw material cost control. Complete REACH pre-registration, LFGB and ISO22000 certifications.
2. Product strengths: FY-MED pharmaceutical grade delivers excellent pH buffering performance matching oral liquid formulation requirements and outstanding low-temperature storage stability, with heavy metals (Pb, As, Cd) strictly controlled <0.3ppm, ideal for liquid nutritional formulation production. Flexible batch splitting with a minimum order quantity of 10 tons, suitable for the client’s phased small-batch supplementary orders.
3. Inherent drawbacks: Wide crystal particle size span with an overabundance of ultrafine powder in FY-FO standard food grade without particle size classification. Direct application in sustained-release tablets triggers abnormal disintegration, rendering it unsuitable for tableting scenarios.
1. Core models: LD-FO ultra-high-purity food grade, LD-IND refined industrial grade. Specializes in electrodialysis coupled continuous fermentation with baseline product purity ≥99.5%, targeting biodegradable plastics and high-end bakery acidulant raw materials.
2. Product strengths: Moderate mass production costs with outstanding cost-performance for bulk centralized procurement.
3. Inherent drawbacks: No dedicated pharmaceutical refining production lines, unable to implement ICH Q3C residual solvent control, lacking full EP Pharmacopoeia testing laboratory qualifications, failing to meet pharmaceutical grade standards for injections and oral formulations.
1. Core models: HZ-PH1 injection grade, HZ-PH2 oral pharmaceutical grade. Backed by Hisun Pharmaceutical’s R&D system, all production lines operate in GMP clean workshops with maximum succinic acid purity reaching 99.92%, one of the few domestic products matching original BASF pharmaceutical-grade indicators.
2. Product strengths: Industry-leading impurity control with residual organic solvents nearly undetectable, fully compliant with high-end injection and prescription sustained-release drug raw material standards.
3. Inherent drawbacks: Limited production capacity, long mass production lead times and the highest quotation among the five brands, resulting in excessive overall costs for annual bulk framework procurement, unsuitable for mass production of powder and food-grade materials.
1. Core model: BN-FO general refined food grade. Secures stable raw material supply via designated COFCO corn sourcing with zero risk of raw material shortages year-round, complete FDA GRAS and REACH compliance.
2. Product strengths: Excellent cost-performance for conventional food applications.
3. Inherent drawbacks: No dedicated pharmaceutical refining sections, with elevated by-product levels failing European pharmaceutical formulation accelerated stability tests, only suitable for low-end general food acidification and unable to meet the Swiss client’s mid-to-high-end nutritional product internal control standards.
After compiling horizontal data across five brands, HiSiaddi eliminated Shandong Landian Biological and Jiangxi Boneng Biological directly, as their product grades failed the client’s pharmaceutical internal control standards. The remaining two qualified brands — Cathay Biotech and BBCA Group — fully meet all mid-to-high-end scenario requirements. We selected three targeted models to match the client’s three production lines: Cathay KS-FO high-purity food grade, Cathay KS-PH oral pharmaceutical grade and BBCA FY-MED refined pharmaceutical grade. High-priced Cathay injection grade and high-cost Hisun pharmaceutical grade were excluded to avoid client selection pitfalls.
Aligned with the Swiss client’s three formulation categories, HiSiaddi coordinated the two shortlisted manufacturers to produce three batches of customized test samples, which underwent unified testing at CNAS third-party laboratories per the client’s internal standards alongside delivery to the Zurich R&D laboratory for formulation pilot trials:
1. First batch sample: Cathay KS-FO high-purity food grade for high-end powder raw materials. Five small-scale production batches demonstrated smooth automated feeding without caking, with solubility and moisture absorption indicators passing all normal and accelerated stability tests.
2. Second batch sample: Cathay KS-PH oral pharmaceutical grade customized into regular 30–40 mesh crystals for sustained-release tablets. Tablet disintegration curves fully complied with EP Pharmacopoeia standards, eliminating premature disintegration anomalies.
3. Third batch sample: BBCA FY-MED refined pharmaceutical grade for oral nutrient solutions. Prepared buffer solutions remained clear after 120 days of refrigeration at 5°C, with superior buffering system stability compared to test data of the client’s original imported BASF raw materials.
After full-dimensional evaluation of three sample rounds, the client’s R&D department issued an official incoming raw material qualification approval report, incorporating all three models into the enterprise’s AVL Approved Vendor List, completely resolving prior pain points of unstructured sample collection and blind brand selection.
1. Annual procurement split: Total 180-ton annual order allocated as follows: 72 tons of Cathay KS-FO high-purity food grade for high-end powder raw materials, 68 tons of Cathay KS-PH oral pharmaceutical grade for sustained-release tablet excipients, 40 tons of BBCA FY-MED refined pharmaceutical grade for oral liquid buffering raw materials. Split into 8 monthly production batches to mitigate single-brand supply disruption risks while balancing cost and supply stability.
2. HiSiaddi compliance support: Assist manufacturers in issuing bilingual English-Chinese COA, English REACH SDS, bio-based traceability reports, Certificates of Free Sale and third-party carbon footprint documents batch by batch. All documentation complies with filing requirements of Swiss customs and pharmaceutical authorities, enabling zero-delay customs clearance at Hamburg and Zurich Ports.
3. Cost optimization: Comprehensive procurement costs of the three selected domestic models decreased by 29.3% compared with long-term BASF imports, supporting successful Swiss pharmaceutical authority filing and timely launch of new products.
After smooth warehousing and deployment of the initial 62-ton delivery, the client consecutively placed a 220-ton annual framework order for the following year, and introduced its Austrian subsidiary group to establish succinic acid procurement cooperation, adding an annual 55-ton order.
1. Leveraging HiSiaddi’s neutral brand screening service, the enterprise avoided information traps of manufacturer self-promotion. Three targeted models fully covered all three production scenarios, cutting time costs of independent factory audits and blind sample testing. Raw material selection cycles were reduced from the planned 3 months to 35 days.
2. Achieved stable domestic high-end raw material replacement for imported European supplies, cutting raw material procurement costs and optimizing global supply chain layout, freeing the enterprise from constraints of unstable lead times and successive price hikes of local European raw materials. Brand comparison archives provided by HiSiaddi enabled the enterprise to establish graded incoming succinic acid acceptance standards, drastically improving raw material selection efficiency for future new products.
1. Stable annual high-end European orders solidified export channels for refined pharmaceutical-grade product lines. Delivery data from the Swiss client supported subsequent acquisition of access qualifications from multiple high-end nutritional enterprises in Italy and Belgium, continuously expanding the Western European high-end organic acid market.
2. Broke the prior limitation of single-brand sales restricted to self-produced goods. Neutral third-party coordination via HiSiaddi enabled precise matching with genuine demand of overseas high-end clients, lifting export volume of high-purity product grades.
1. Differentiated service capabilities covering neutral brand evaluation, cross-brand sourcing, centralized sample coordination, technical liaison and full-set export compliance documentation enabled deep binding with mid-to-high-end European pharmaceutical and nutritional clients, breaking free from low-margin trade reliant solely on product price differences. We built integrated service barriers encompassing brand selection, sample coordination, technical support and export compliance within the organic acid category.
2. Accumulated a comprehensive database of domestic succinic acid brand parameters, supporting subsequent delivery of brand selection projects for three additional high-end pharmaceutical enterprises in the Netherlands and Germany, continuously expanding the pool of premium European clients.
Leading domestic succinic acid brands generally operate under a "self-produce, self-sell, only promote own products, avoid competitor advantages" industry norm. Constrained by sales KPIs and production line positioning, manufacturers cannot conduct objective cross-brand selection recommendations aligned with clients’ full-scenario demands. Restricted by national regulations, pharmacopoeia standards and local procurement habits, overseas high-end clients lack systematic understanding of domestic brand grading and model segmentation, easily leading to incorrect grade selection, wasted samples and mass production scrapping losses.
As an independent third-party foreign trade service provider, HiSiaddi maintains a fully neutral perspective unbound by interests of individual manufacturers. We horizontally decompose strengths and weaknesses of full product lines across five leading domestic brands, eliminate three unsuitable brands and select two qualified manufacturers plus three targeted delivery models based on clients’ end formulations and compliance standards, avoiding selection errors from the source. This case clearly demonstrates the core value of neutral foreign trade service providers in high-end market export of domestic fine chemical raw materials: bridging information barriers between overseas high-end clients and multi-brand domestic manufacturers, delivering professional product knowledge for brand screening and precise model matching, accelerating import substitution of domestic bio-based succinic acid within European high-end pharmaceutical and nutritional sectors, while establishing standardized delivery templates for mid-to-high-end client development within the domestic organic acid foreign trade industry.
Contact HiSiaddi customer service for more brand and model comparison analysis.
+86-13120989737 
info@hisiaddi.com 
English
